MEDITOXIN® 100u

MEDITOXIN® 100u is a purified botulinum toxin type A complex indicated for both aesthetic and therapeutic use. Developed by Medytox Inc., it is used worldwide under various brand names including Siax®, Botulift®, Cunox®, and Neuronox®. MEDITOXIN® works by blocking neuromuscular transmission, leading to temporary muscle relaxation. It is FDA-approved in several countries for the treatment of glabellar lines, benign essential blepharospasm, spasticity in pediatric cerebral palsy, and post-stroke upper limb spasticity. Clinical studies have confirmed that its efficacy and safety are comparable to OnabotulinumtoxinA (Botox®) at a 1:1 dose ratio.

• Format: Lyophilized white powder in single-use vials
  
• Potency: 100 units of Clostridium botulinum toxin type A per vial
  
• Approval: Registered in 27+ countries
  
• Uses: Cosmetic (wrinkles) and neurological (spasticity, dystonia)
  

MEDITOXIN® should be reconstituted with 0.9% sodium chloride (non-preserved) and administered intramuscularly using fine-gauge needles.

• Dilution Table:
  
  • 1.0 mL → 10 U/0.1 mL
    
  • 2.0 mL → 5 U/0.1 mL
    
  • 4.0 mL → 2.5 U/0.1 mL
    
  • 8.0 mL → 1.25 U/0.1 mL
    
• Administration Guidelines:
  
  • Glabellar lines: Inject 20U across 5 sites (corrugators & procerus)
    
  • Blepharospasm: 1.25–2.5U per site; max 5.0U per site
    
  • Cerebral palsy (spasticity):
    
    • Hemiplegia: 4U/kg
      
    • Diplegia: 6U/kg
      
    • Max: 200U/patient
  • Post-stroke spasticity: Up to 360U depending on muscle group
    
• Repeat Treatment: At minimum intervals of 12 weeks

MEDITOXIN® is indicated for the treatment of several medical and aesthetic conditions related to muscle overactivity or hyperfunction.

Indications:

• Moderate to severe glabellar lines (in adults 18–65)
  
• Benign essential blepharospasm (18+ years)
  
• Equinus foot deformity in pediatric cerebral palsy (2+ years)
  
• Upper limb spasticity post-stroke (20+ years)
  

Contraindications:

• Infection at injection site
  
• Known hypersensitivity to botulinum toxin or excipients
  
• Pregnancy and lactation (precautionary)
  
• Neuromuscular disorders (e.g., myasthenia gravis)

Each vial of MEDITOXIN® 100u contains:

• Clostridium botulinum toxin type A complex – 100 units
  
• Human serum albumin – 0.5 mg
  
• Sodium chloride – 0.9 mg
  

The product is freeze-dried and requires reconstitution with sterile saline before use.

• 1 single-use vial with 100U of freeze-dried powder
  
• Colorless transparent glass container
  
• No preservatives—intended for use in one patient only
  
• Diluent not included; requires sterile saline for reconstitution
  

Yes, MEDITOXIN® can cause localized and systemic side effects, although most are mild and transient.

Common side effects (≥1%):

• Eyelid ptosis (3.2%)
  
• Extraocular muscle disorder
  
• Localized pain or swelling
  
• Headache, nausea, flu-like symptoms
  

Less common but serious:

• Allergic reactions
  
• Dysphagia or breathing difficulties
  
• Spread of toxin effects beyond the injection site
  

Clinical Data: Adverse event rates are comparable to Botox®, with no significant difference in severity or incidence.

Proper storage is essential to preserve product efficacy and safety.

• Before reconstitution:
  • Store at 2°C to 8°C (refrigerated) or below -5°C (frozen)
  • Protect from light
• After reconstitution:
  • Use within 24 hours
  • Store at 2°C to 8°C during this time
  • Ensure solution is clear and free of particles
• Shelf Life: 36 months from manufacturing date